← ANALYST RATINGS · TIPRANKS
CAMP4 Therapeutics Corporation (CAMP): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $10.00, the highest $15.00, the lowest $7.00. The average is +215.5% from the last price of $3.17.
Analyst ratings 9
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $8.00 | Buy | +152.4% | Initiated | 15.10.26on TipRanks Oct 16 05:50 | +0.3%next day −7.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Sell | −5.4% | Downgrade | 14.10.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +10.4% | Reiterated | 14.10.26on TipRanks 08:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 | Hold | +26.2% | Reiterated | 29.09.26on TipRanks 09:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 | Hold | +26.2% | Reiterated | 29.09.26on TipRanks 09:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 | Hold | +26.2% | Reiterated | 29.09.26on TipRanks 09:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Sell | +10.4% | Downgrade | 29.09.26on TipRanks 09:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 | Hold | +26.2% | Reiterated | 29.09.26on TipRanks 09:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +10.4% | Reiterated | 29.09.26on TipRanks 09:05 | — | |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $8.00 | Buy | +152.4% | Reiterated | 29.09.26on TipRanks 07:25 | +1.7%next day +3.5% · 5 days −0.7% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $15.00 | Buy | +373.2% | Reiterated | 29.09.26on TipRanks 06:50 | +1.7%next day +3.5% · 5 days −0.7% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $6.50 → $6.00−7.7% | Buy | +89.3% | Reiterated | 29.09.26on TipRanks 06:10 | +1.7%next day +3.5% · 5 days −0.7% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 29.09.26on TipRanks 05:15 | +1.7%next day +3.5% · 5 days −0.7% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $7.00 | Buy | +120.8% | Reiterated | 28.09.26on TipRanks Sep 30 02:20 | −1.0%next day +1.7% · 5 days +3.0% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $9.00 | Buy | +183.9% | Upgrade | 22.06.26on TipRanks Jun 23 08:08 | +2.0%next day +5.3% · 5 days +6.2% | ↗ |
| Seema Sheoran★★★★★★★★★★#8280 · hits 33% · avg +0.9% | Rodman & Renshaw | $7.00 | Buy | +120.8% | Initiated | 14.04.26on TipRanks 06:55 | −3.8%next day +0.8% · 5 days +0.8% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $8.00 → $9.00+12.5% | Buy | +183.9% | Reiterated | 02.04.26on TipRanks 06:15 | +0.1%next day 0.0% · 5 days −3.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering CAMP4 Therapeutics Corporation
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.00 at a price of $4.04 (+122.8%); now: $8.80 at $3.17 (+177.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 | 3 | 4 |
| Buy | 2 | 2 | 3 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 19.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.19 (from $-0.28 to $-0.13). Last quarter: $-0.58.
Sales
Next quarter’s sales estimate — $2M (from $0M to $4M). Last quarter: $2M.
Best top-analyst consensus in the sector · General
About CAMP4 Therapeutics Corporation
- CEO: Joshua Mandel-Brehm
- Employees: 48
- One Kendall Square Bldg 1400 West, 3rd Floor, Cambridge, MA, 02139, US
- www.camp4tx.com
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
Data from the stock’s TipRanks forecast page, read 17 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗